Physician Payment Disclosure Under Health Care Reform: Will the Sun Shine?

Mackey, Tim K.; Liang, Bryan A.

doi:10.3122/jabfm.2013.03.120264

Cited by 16 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In "Physician Payment Disclosure Under Healthcare Reform: Will the Sun Shine?" (grand challenges 8, 10, 11, and 13), Mackey and Liang 13 illustrate the intent of regulation efforts to control pharmaceutical costs and mitigate conflicts of interests for providers. Evans et al 14 (grand challenges 10, 12, and 13) have an answer to the pharma dilemma: engage in a pharma-free practice redesign.…”

Section: Influences Of the Pharmaceutical Industrymentioning

confidence: 99%

Communities of Solution: Partnerships for Population Health

Griswold

Lesko

Westfall

2013

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Section: Influences Of the Pharmaceutical Industrymentioning

confidence: 99%

Communities of Solution: Partnerships for Population Health

Griswold

Lesko

Westfall

2013

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

“…16,22 Another option is to seek clarification on whether the statutory language of the Sunshine Act permits CMS to add DTCA reporting as a new reportable category under existing regulations. 16 Consumers, public health and health care professionals, and policy makers should collectively advocate for greater transparency of DTCA to better understand its influence on pharmaceutical and health care utilization and consumer behavior. Physicians play an important role in advocating for this change because their clinical practice and relationship with patients could be the most adversely affected and because of the heightened need for physicians to guide patients concerning DTCA claims.…”

Section: Shining the Light On Physician-directed Promotion But Not Dmentioning

confidence: 99%

“…16 This policy change, largely a response to concerns over physicianindustry conflicts of interest, will provide detailed and validated data regarding important forms of national physician-directed promotion expenditures that will be public and freely available. 16 Missing from this potentially groundbreaking legislation, however, are any requirements for transparency and reporting of DTCA expenditures by industry. Specifically, the regulations only cover certain forms of promotion directed to licensed physicians and teaching hospitals, not promotion directed to the consumer.…”

Section: Shining the Light On Physician-directed Promotion But Not Dmentioning

confidence: 99%

“…16 The law mandates that drug and device manufacturers now publicly report certain payments made to physicians and teaching hospitals (including entertainment, gifts, food, travel, consulting fees, honoraria, education or conference fees, and other forms of "transfers of value") annually, with monetary penalties for noncompliance. 16 This policy change, largely a response to concerns over physicianindustry conflicts of interest, will provide detailed and validated data regarding important forms of national physician-directed promotion expenditures that will be public and freely available. 16 Missing from this potentially groundbreaking legislation, however, are any requirements for transparency and reporting of DTCA expenditures by industry.…”

Section: Shining the Light On Physician-directed Promotion But Not Dmentioning

confidence: 99%

“…As has already happened in states such as Minnesota, Vermont, Maine, and West Virginia, state legislators eager to understand the health and economic impact of DTCA could enact state legislation requiring disclosure of DTCA expenditures targeted at their residents (a requirement not preempted by the Sunshine Act). 16,22 Another option is to seek clarification on whether the statutory language of the Sunshine Act permits CMS to add DTCA reporting as a new reportable category under existing regulations. 16 Consumers, public health and health care professionals, and policy makers should collectively advocate for greater transparency of DTCA to better understand its influence on pharmaceutical and health care utilization and consumer behavior.…”

mentioning

confidence: 99%

See 2 more Smart Citations

It's Time to Shine the Light on Direct-to-Consumer Advertising

Mackey

Liang

2015

The Annals of Family Medicine

Self Cite

View full text Add to dashboard Cite

Pharmaceutical marketing is undergoing a transition as the business, delivery, and consumption of health care have increasingly become part of a growing digital landscape. Changes in pharmaceutical promotion also coincide with federal "sunshine" regulations newly implemented under the Affordable Care Act that require disclosure of certain marketing and industry payments to physicians. Collectively, these trends could lead to fundamental shifts in physician-directed and direct-to-consumer advertising (DTCA) that have yet to be adequately identified or explored. In response, we advocate for greater DTCA transparency, especially in the emerging digital forms of DTCA, to complement forthcoming sunshine transparency data. This will allow more robust study and understanding of changes in overall pharmaceutical marketing trends and their impact on health care consumption and behavior. This can also lead to more targeted state and federal policy interventions leveraging existing federal transparency regulations to ensure appropriate marketing, sales, and consumption of pharmaceutical products. BACKGROUND Over the past few decades, US pharmaceutical marketing has evolved in new and unexpected ways, as the business of health care has become part of a growing "eHealth" landscape. Increasingly, patients and other consumers, clinicians, and the industry have started to embrace emerging forms of digital technology (eg, the "health Internet," mobile health applications, self-tracking devices, and social media) that can influence health care information sourcing, consumption, and delivery. As an indication of this shift to "all things digital," the Pew Research Internet Project reports that 72% of surveyed US adults looked for health information online within the past year, 69% track at least 1 health indicator such as weight, exercise, symptoms, blood pressure, or sleeping patterns (with 21% of respondents using a form of technology to do so), and 52% of smartphone users use their devices to search for medical/health information. 1With consumers increasingly using information technology to deal with health issues, and with pharmaceutical manufacturers using directto-consumer advertising (DTCA) on the Internet, in social media, and through mobile applications (collectively "eDTCA"), [3][4][5][6] traditionally dominant forms of pharmaceutical marketing, which include physician-directed promotion and advertising in traditional media (eg, television, radio, print, and outdoor advertisements) might also be changing. 8 This led to a proliferation of drug advertisements on TV and in print to which the vast majority of Americans were exposed, likely prompting patients to request a promoted drug from their physician. 9,10 After hitting a peak of $5.89 billion in 2006, DTCA began to decline, with spending estimated to be $4.37 billion in 2010. This decrease has largely been attributed to dwindling drug pipelines, blockbuster patent expirations, and the recent global economic slowdown, 11-13 although certain subcategories (eg, t...

show abstract